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ABSTRACT 17 
A persistent challenge in enhancing gene therapy is the transient availability of the target gene 18 
product. This is particularly true in tissue engineering applications. The transient exposure of 19 
cells to the product could be insufficient to promote tissue regeneration. Here we report the 20 
development of a new material engineered to have a high affinity for a therapeutic gene product. 21 
We focus on insulin-like growth factor–I (IGF-I) for its highly anabolic effects on many tissues 22 
such as spinal cord, heart, brain and cartilage. One of the ways that tissues store IGF-I is through 23 
a group of insulin like growth factor binding proteins (IGFBPs), such as IGFBP-5. We grafted 24 
the IGF-I binding peptide sequence from IGFBP-5 onto alginate in order to retain the 25 
endogenous IGF-I produced by transfected chondrocytes. This novel material bound IGF-I and 26 
released the growth factor for at least 30 days in culture. We found that this binding enhanced the 27 
biosynthesis of transfected cells up to 19-fold. These data demonstrate the coordinated 28 
engineering of cell behavior and material chemistry to greatly enhance extracellular matrix 29 
synthesis and tissue assembly, and can serve as a template for the enhanced performance of other 30 
therapeutic proteins. 31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
*Graphical Abstract
3 
1. INTRODUCTION45 
A number of recent studies have focused on delivering therapeutic proteins using gene 46 
therapy to enhance the repair of skeletal muscle, brain, spinal cord, and cartilage[1–3]. Many of 47 
these studies have focused on a variety of membrane repair proteins, transcription factors, and 48 
growth factors to increase cellular synthesis and control paracrine cascades[1,4,5]. However, one 49 
of the main limiting factors in the efficacy of gene therapy is the transient availability of the gene 50 
product, regardless of the vector used. For example the use of gene therapy in cartilage repair has 51 
targeted increased growth factor production; however, the desired gene product is typically 52 
upregulated for up to two weeks[6,7]. Further, the highest concentrations of growth factors are in 53 
the first days after transfection, and have the potential to produce supra-therapeutic, or toxic 54 
levels of the growth factor[8]. 55 
One of the proteins commonly targeted for cartilage repair in gene therapy is insulin-like 56 
growth factor–I (IGF-I)[7–10]. Various viral and nonviral vectors have been used to 57 
transduce/transfect chondrocytes to upregulate IGF-I synthesis prior to therapeutic cell 58 
delivery[7,11–13]. Although IGF-I expression can remain elevated for a month or more[14], this 59 
expression decreases with time, and is often low by 2 weeks[7,15]. This is an extremely short 60 
time compared to the 6-12 months typically needed for effective cartilage repair[16], and may 61 
not induce optimal repair in vivo. As such, there is a great need for approaches to extend the 62 
availability of IGF-I for cartilage therapy. 63 
In tissues such as cartilage, IGF-I is retained in the tissue by a family of binding proteins 64 
called insulin-like growth factor binding proteins (IGFBPs). These binding proteins are highly 65 
specific to IGF-I, with binding affinities of 1-10 nM[17]. IGFBPs also bind to cartilage enhanced 66 
cellular matrix (ECM), acting as both a sink and source for the growth factor as needed[18]. It 67 
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has been shown that IGFBP-5 has a specific localized small domain that is largely responsible 68 
for its high affinity binding to IGF-I[17]. 69 
Cell-based gene therapy for articular cartilage repair requires a means of delivering cells to the 70 
site in need of repair[19]. There has been increased attention to the development of biomaterials 71 
that prolong release and expression of gene products. Some of those biomaterials are chitosan, 72 
poly-L-lactic acid (PLLA), poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHx), 73 
polyethyleminine (PEI), and polyethyleneglycol (PEG). Chondrocytes have been cultured in 74 
chitosan-fabricate and a plasmid DNA scaffold to study cell proliferation, adherence, and 75 
transforming growth factor-ß1 (TGF-ß1) expression[20] and chitosan-pEGFP nanoparticles have 76 
been used to transfer exogenous genes into primary chondrocytes for the treatment of joint 77 
diseases[21]. Trimethylated chitosan (TMO) was synthesized from oligometric chitosan to 78 
deliver luciferase plasmid DNA to epithelial cells[22].  PLLA has been used with mesenchymal 79 
stem cells (MSCs) transfected with adenoviral SOX-9 to differentiate monolayer MSCs into 80 
chondrocyte-like cells[23]. PHBHHx scaffolds have been seeded with chondrocytes which 81 
employed tetracycline (Tet-on) to induce Sox9 expression[24]. Modified polyethylenimine (PEI) 82 
exhibited lower toxicity and higher gene expression of plasmid DNA in COS-7 cells and 83 
HepG2cells[25]. Polyethylene glycol-grafted polyethylenimine (PEG-PEI) has been used as a 84 
vector to deliver gene products to adipose stem cells to differentiate them to cartilage or 85 
osteoblast cells[26]. Hydrogels, including alginate, have also been shown to serve this 86 
purpose[27]. There are numerous examples of short peptide sequences being grafted to materials 87 
to enhance cell adhesion[17,28,29]. Similarly, materials have been modified to contain heparin-88 
like carbohydrate components which have been shown to enhance binding of growth factors such 89 
as FGF-2[30]. All of the previous materials have been used to promote gene delivery and to 90 
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prolong the release and expression of the gene product, but none of these materials have 91 
interacted in any specific way with the proteins that are targeted for production by the cells. The 92 
goal of this study was to develop a material that could bind to the targeted gene product and 93 
assess whether that binding will enhance matrix production. To our knowledge, peptide-based 94 
modification of materials to localize growth factors has not been reported. 95 
Here we demonstrate the development of a new material with high affinity for IGF-I by 96 
grafting a binding peptide sequence from IGFBP-5 onto alginate. This new material greatly 97 
extends the availability of the growth factor during chondrocyte culture and enhances cartilage 98 
matrix biosynthesis up to 19-fold. 99 
100 
2. MATERIALS AND METHODS101 
2.1 Chemistry 102 
UP LVG alginate (from NovaMatrix®) was modified with carbodiimide chemistry[28]. 103 
100 mg alginate (1% w/v alginate solution) was dissolved in 0.1 M of 1-(N-morpholino) 104 
ethanesulfonic acid (MES) buffer (Sigma-Aldrich) at pH 6.5. The reaction scheme is shown in 105 
Figure 1 where amide linkages were obtained by adding 2.5 mM of 1-ethyl-106 
(dimethylaminopropyl) carbodiimide (EDC) (Sigma-Aldrich) and 1.2 mM of sulfo-N-107 
hydroxysuccinimide (NHS) to raise the efficiency of amide bond formation (Pierce 108 
Chemical)[28]. 1 mg of GGG-K(ivDde)PLALL peptide sequence (INNOVAGEN) was added 109 
after 5 minutes; the solution was left to react for 20 hrs. The reaction was quenched with 0.026 110 
mM of hydroxyamine hydrochloride (Sigma-Aldrich) at 20 hrs. Alginate solution was purified 111 
by dialysis (3500 MWCO) (Fisher Scientific) with different salt concentrations varying 115 mM 112 
to 0 mM. Samples were stored at -80 °F for 24 hours and then they were lyophilized for 24 113 
6 
hours.  The additional 3 glycines at the N- terminus of this synthetic peptide sequence were added 114 
in order to provide a linker layer that would more fully expose the active peptides in the 115 
sequence once the peptide was bound to a surface. The lysine on this sequence was protected 116 
from unwanted chemical reactions by an ivDde protecting group; this was removed using 5% 117 
hydrazine, anhydrous (Sigma) in dimethylformamide (DMF). Following the deprotection step, 118 
the modified alginate solution GGG-KPLALL (KPLHALL) was purified by dialysis (3500 119 
MWCO) (Fisher Scientific) with DI H2O for 24 hours. Samples were stored at -80 °F for 24 120 
hours and then they were lyophilized for
 24 hour
s.
  121 
2.2 Nuclear Magnetic Resonance Studies 122 
The freeze-dried KPLHALL alginate and unmodified alginate were dissolved in D2O at 123 
0.0012% w/v. There were three groups: alginate, a mixture of alginate with free KPLHALL 124 
peptide, and KPLHALL-grafted alginate. 
1
H nuclear magnetic resonance (
1
H NMR) spectra were125 
recorded on 600MHz Varian Inova NMR. 
1
H NMR was normalized to residual solvent D2O. The126 
final molar concentration of peptide KPLHALL grafted in alginate was obtained by integrating 127 
the area under the curve with MNova NMR Software, 100 µM of binding sites of KPLHALL 128 
(0.3% of degree of graft on alginate backbone). Also, diffusion ordered spectroscopy (DOSY) 129 
was performed to demonstrate stable attachment of the peptide sequence to the alginate. 130 
2.3 Surface Plasmon Resonance Studies 131 
Surface Plasmon Resonance (SPR) measurements were performed with an SPR 132 
Refractometer Instrument (Reichert, Inc., Depew, NY). A range of KPLHALL concentrations 133 
from 0 to 100 µM was achieved by mixing the 100 µM KPLHALL with unmodified alginate in 134 
varying ratios. Modified and unmodified alginate were bound to 50 nm thick gold chips (Fischer 135 
Scientific, Pittsburg, PA) using carbodiimide chemistry. Samples were run at 25° C in buffer for 136 
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10 minutes per sample, using a constant flow rate of 25 μl /min over the surface of the SPR chip. 137 
Concentrations of IGF-I ranged from 5 to 3000 nM. PBST (PBS plus 0.05% v/v Tween 20) was 138 
used as both the sample and flow buffer. After each binding experiment, the surface was 139 
regenerated with 40 mM HCl. The sensorgram profiles were analyzed using SigmaPlot where 140 
response to equilibrium was calculated with an three parameter exponential rise to maximum 141 
model and then a Langumir binding model was used to determine the binding constant (KD) [31]. 142 
2.4 Analysis 143 
The microrefractive index unit at equilibrium was measured for each concentration of IGF-I as it 144 
flowed through the chip (Equation 1). 145 
            
 
      
 
 
  
Where, Req is the refractive index unit at equilibrium, t is time, t0 is the time after baseline, and 146 
Ʈ is the exponential time constant. 147 
KD was calculated by fitting the data to Langmuir’s Affinity Kinetics Model [31] (Equation 2) 148 
    
            
         
149 
Req is the response at equilibrium for each curve; [IGF-I] is the concentration of IGF-I; Rmax is 150 
the maximum equilibrium response and KD is the binding affinity constant. The dissociation rate 151 
constant (koff) was calculated by fitting the dissociation phase[31] (Equation 3) 152 
                 
 
      
    
 
  
Where, RT is the total response where it is assumed that the total complex concentration of IGF-I 153 
and KPLHALL [IGF-I*KPLHALL]TOTAL is proportional to the total response (RT). Req is the 154 
response at equilibrium for each curve and Roff is the equilibrium response at the end of the 155 
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dissociation phase. The experiment was measured at different times, t (time where dissociation 156 
finished) and t1 (time where dissociation started). 157 
Furthermore, the association rate constant (kon) of each IGF-I concentration was calculated as 158 
(Equation 4) 159 
  
    
   
160 
2.5 Cell Culture and Matrix Synthesis: 161 
Chondrocytes were isolated as previously described[7,32]. Articular cartilage was 162 
harvested from stifle (knee) condyles of 1-3 day old bovids (Bos taurus). Articular cartilage was 163 
washed with PBS and 1% antibiotics and antimycotic. Chondrocytes were then isolated by 164 
adding 0.3%  type 2 collagenase (catalogue number LS004177,  Worthington Biochemical, 165 
Lakewood, NJ) overnight. Isolated chondrocytes were washed and suspended in DMEM 166 
containing 100 U/mL penicillin, 100 µg/mL streptomycin, and 10% fetal bovine serum (FBS) 167 
and placed in T-75 flasks plates at 60% confluency at 37˚C in 5% CO2. After 48 hours, cells 168 
were transfected using two different complexes, made 30 minutes before transfection, at a ratio 169 
of 3:1[7,10,33]: FuGENE
®
6 (Roche Applied Science, Indianapolis, IN) + pAAV/IGF-I or170 
FuGENE
®
6+pAAV/ MCS (Empty). After 16 hours, the transfection was stopped by replacing171 
the culture medium with 5 mL of fresh media without FBS, and 100 U/mL penicillin, 100 µg/mL 172 
streptomycin. Afterwards, cells were trypsinized and mixed with 2% (w/v) modified or 173 
unmodified alginate. These culture, encapsulation, and transfection methods were selected based 174 
on previous work [9] demonstrating the successful formation of tissue in vivo using these 175 
protocols.  176 
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A range of KPLHALL concentrations from 0 to 100 µM was achieved by mixing the 100 177 
µM KPLHALL with unmodified alginate in varying ratios. Cells were encapsulated in beads 178 
formed by extrusion through a 22-gauge needle into a 102 mM CaCl2 solution. Beads were 179 
incubated with DMEM without FBS for 30 days; beads were collected every six days. 180 
2.6 Biochemical Analysis 181 
Beads collected every six days for 30 days were used to measure DNA, 182 
glycosaminoglycan (GAG) and hydroxyproline (HYPRO) content. DNA content was measured 183 
via Hoechst dye assay[34]. GAG content was measured using the DMMB dye-binding assay[35], 184 
and HYPRO content was measured using DMAB dye assay[36]. Syntheses of GAG [35] and 185 
HYPRO [36] were used as the primary measure of chondrocyte metabolic activity. The kinetics 186 
of GAG and HYPRO accumulation were fitted to an established model of matrix synthesis to 187 
calculate steady-state GAG and HYPRO content [37] (Equation 5). 188 
                      
  
   
Where, [ECM] is the matrix synthesized by the transfected or control of chondrocytes in 189 
the different concentrations of KPLHALL. [ECM]SS is steady state matrix production produced 190 
by the chondrocytes at different concentrations of KPLHALL.  Each steady state value was 191 
normalized to alginate (0 µM) steady state value for GAG and HYPRO. These normalized 192 
steady-state values of GAG and HYPRO synthesis were used to determine the effect of 193 
KPLHALL content on chondrocyte matrix synthesis using a generalized variable slope 194 
concentration–response model (Equation 6) [37]. 195 
       
          
          
                 
   
         
    
 
          
Where, [ECM]SS is the steady state matrix production, [ECM0µM]SS is the steady state matrix 196 
production, [ECM]max is the maximum stimulation, [ECM]min is the minimum stimulation, 197 
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[KPLHALL] is the concentration of KPLHALL- modified alginate, and EC50 is the dose required 198 
to produce 50% response. 199 
Beads from day 30 were collected for immunohistochemistry analysis. Samples were 200 
treated with citrate antigen retrieval buffer for 10 minutes at 90°C. Slides were then washed with 201 
TBS/TWEEN20 and PBS. Samples were placed in humidity chambers for 30 minutes with 3% 202 
hydrogen peroxide. Blocking solution (goat serum) was added and incubated for 1 hour at room 203 
temperature. Afterwards the primary antibody Rb pAb for IGF-I (ab40657) was applied and left 204 
overnight at 4°C. Negative controls were obtained by omitting the primary antibody to a section 205 
on each slide (See supplementary figure S1). Next Rabbit IgG for secondary antibody was 206 
applied for 30 minutes at room temperature, followed by ABC reagent (Vectastain PK-4000, 207 
Vector Labs). Slides were developed with DAB peroxidase (Vector Labs) for approximately 3 208 
minutes. 209 
2.7 Statistical Analysis 210 
GAG and HYPRO data are expressed as mean ±SD. The effect of culture time and 211 
transfection were analyzed by 2-way ANOVA using Tukey’s t-test for post hoc analysis 212 
performed in SigmaPlot 11 (SYSTAT, Chicago, IL), with significance determined with p<0.05.213 
The temporal patterns in GAG and HYPRO data were then fit to equation 5 using SigmaPlot 11, 214 
which calculated best fit values of [ECM]SS and τ, with the uncertainties in these fits expressed as 215 
standard error. 216 
Each steady state values and standard errors were normalized to alginate (0 µM) steady 217 
state value for GAG and HYPRO. The normalized values were fitted to Equation 6 using 218 
software SigmaPlot 11, which enabled the calculation of best fit values for EC50, [ECM]max, and 219 
[ECM]min values and their uncertainty, expressed as standard error. Statistical differences 220 
11 
between EC50, [ECM]max, and [ECM]min were determined by an unpaired t test using GradPad 221 
Prism (GraphPad, Inc., La Jolla, CA). 222 
223 
3. RESULTS224 
3.1 Generation and Characterization of Hydrogels with Affinity for IGF-I 225 
The peptide sequence KPLHALL from the hydrophobic binding pocket of IGFBP-5 was 226 
chosen as a candidate for enhancing IGF-I binding based on analysis of the crystal structure of 227 
IGFBP-5 /IGF-I complex. These data showed that 6 of the 7 amino acids in this peptide sequence 228 
were within 4Å of IGF-I when the complex is formed, enabling a high level of affinity [38]. 229 
The high affinity sequence was synthesized and grafted to alginate via previously 230 
established carbodiimide/sulfo-NHS chemistry[39](Fig 1A). The modification of alginate was 231 
confirmed by 
1
H NMR analysis, using the leucine peaks at ~0.7 ppm to both demonstrate 232 
successful grafting and measure the amount of conjugated peptide (Fig 1B). Additionally the 233 
stability of the peptide graft was demonstrated by diffusion ordered NMR (DOSY), which 234 
showed the persistence of leucine peaks in the grafted material (See supplementary figure S2). 235 
Analysis of IGF-I binding to modified and control alginate via surface plasmon resonance 236 
(SPR) demonstrated significant enhancement of binding by the modified material (Fig1C). The 237 
dissociation constant (KD) decreased from 513 nM to 50 nM due to modification with 238 
KPLHALL (Fig1C). This level of affinity for IGF-I was lower than that for full length of 239 
IGFBP-5 (KD=3.7 nM), but similar to a truncated form of IGFBP-5 containing only the binding 240 
pocket (KD=37 nM)[17]. 241 
3.2 Enhancement of IGF-I Binding and Matrix Production 242 
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The enhanced binding demonstrated by KPLHALL-modified alginate motivated the 243 
hypothesis that this material would retain IGF-I produced by encapsulated chondrocytes. To test 244 
this hypothesis, articular chondrocytes were transfected with an adeno-associated virus-based 245 
plasmid vector (pAAV/IGF-I), carrying human IGF-I cDNA (transfected chondrocytes) or with 246 
empty vector (control chondrocytes) and encapsulated as previously described[33,39] in 247 
modified and unmodified alginate and cultured for 30 days.  248 
We have previously shown that IGF-I transfection is highly efficient, but also transient, 249 
with enhanced IGF-I expression subsiding within 6 days[7,33]. Consistent with this data, 250 
immunohistochemistry staining of unmodified alginate (i.e. 0 µM binding peptide) cultures 251 
showed minimal presence of IGF-I at 30 days (Fig.2). In contrast, control chondrocytes cultured 252 
in alginate modified with KPLHALL showed enhanced retention of IGF-I at 30 days, with IGF-I 253 
retention proportional to the concentration of the grafted binding peptide. This enhancement was 254 
greater in chondrocytes transfected with pAAV/IGF-I, where the highest concentrations of 255 
binding peptide (i.e. 33µM and 100 µM) resulted in robust staining for IGF-I at 30 days (Fig.2). 256 
Both empty vector control and pAAV/IGF-I transfected chondrocytes showed 257 
accumulation of the principal cartilage matrix components with time. Transfection with 258 
p/AAV/IGF-I enhanced accumulation of glycosaminoglycan (GAG) (p<0.001 by 2-way 259 
ANOVA) (Fig3A) and collagen, as indicated by hyproxyproline (HYPRO) (p<0.001) when 260 
compared to empty vector controls (Fig.3B). These typically reached steady state after two 261 
weeks in culture. The average of the time constants (τ) varied from 5.4 ± 3.6 hr to 10.0 ± 8.0 hr 262 
for GAG; tau values varied from 3.0 ± 3.7 hr to 27.9 ± 7.2 hr for HYPRO. The presence of 263 
peptide binding enhanced matrix synthesis in empty vector and pAAV/IGF-I transfected cultures 264 
(*p<0.001 by 2-way ANOVA) for both GAG and HYPRO. In IGF-I transfection had a dramatic 265 
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effect on HYPRO production both in the presence and absence of the binding peptide (*p<0.01 266 
by 2-way ANOVA). 267 
To understand the effect of IGF-I retention via binding peptide sites, the steady-state 268 
matrix contents were calculated using an established kinetic model [37]. For each culture 269 
condition, steady state matrix contents were normalized to the unmodified alginate (0 µM), 270 
which revealed that matrix synthesis was clearly dose-dependent (R
2
>0.93 for all fits) on binding271 
peptide density (Fig.4A). For the control cells, enhancement of GAG and HYPRO synthesis 272 
were 1.6 and 3-fold, respectively. This effect was more dramatic in transfected cells, with GAG 273 
and HYPRO synthesis upregulated 6.9 (*p<0.0001 by unpaired t test) and 19.4-fold (%p<0.02 by 274 
unpaired t test), respectively. For all cultures, EC50 for enhancement of synthesis ranged from 17 275 
to 41 µM KPLHALL. 276 
4. DISCUSSION277 
These data illustrate that the biomimetic modification of alginate with a binding peptide 278 
from IGFBP-5 enables high affinity binding of IGF-I. The data further demonstrate that this 279 
modification extend the presence of the growth factor in cell-seeded constructs to at least one 280 
month, and that this extended presence of IGF-I in turn substantially enhances cartilage matrix 281 
synthesis. 282 
Producing materials that specifically bind IGF-I present specific technical challenges. 283 
Proteins that are known to bind IGF-I have complex 3D configurations that stabilize the 284 
formation of the binding protein-IGF-I complex[38]. IGFBP-5, which has 252 residues, and 285 
mini-IGFBP-5, which has 52 residues, have binding affinities of 3.7 nM and 37 nM respectively. 286 
Grafting such proteins to a material to enhance IGF-I binding would be technically challenging 287 
and expensive, due to the cost of producing the protein recombinantly. Additionally, stability of 288 
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the grafted material would be of great concern. Grafting shorter peptides would solve this 289 
problem; however it is not clear whether shorter peptides would produce high affinity binding. 290 
Here we showed that grafting a seven peptide sequence from the binding pocket of IGFBP-5 to 291 
alginate produced a material with high affinity (KD = 50 nM). This peptide sequence is short 292 
enough that folding is likely absent or minimally important. However, it is important to note that 293 
grafting to alginate via the Ɛ amino group in the lysine residue of the peptide rather than the 294 
glycine leader sequence eliminated the beneficial effect on matrix synthesis (data not shown). 295 
This data suggests that some amount of leader sequence is necessary for proper binding of IGF-I 296 
to the modified alginate. Additionally, the affinity may be aided by the fact that alginate is a 297 
polyanion and IGF-I is positively charged (pI = 8.5) [40], and charge based interaction may play 298 
a role in aiding binding. Nevertheless the significant enhancement of IGF-I binding by the 299 
addition of a short peptide may provide a template for targeted modification of biomaterials for 300 
growth factor binding.  301 
Other studies have explored alternative approaches for expanding the time of IGF-I 302 
action through controlled delivery. For example, the interaction of IGF-I with the cartilage ECM 303 
has been altered by generating a recombinant fusion protein of IGF-I with a heparin binding 304 
domain[41]. This modified IGF-I bound to heparin sulfate and chondroitin sulfate with high 305 
affinities (21 nM and 172 nM) and extended the retention time of the growth factor in 306 
cartilage[41]. Other approaches for delivery include gene-activated matrix (GAM) [42] 307 
materials, in which a material  is loaded with a plasmid that is released slowly to the cells. 308 
Similarly IGF-I peptide was released from degradable microparticles to achieve delivery over ~2 309 
weeks[43]. The approach described in the current paper compliments these previously described 310 
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approaches and provides additional flexibility for tuning both cellular and matrix responses over 311 
many weeks. Additionally, we can use our modified alginate with other methods of gene therapy. 312 
Similarly this modified material may be helpful in enhancing other methods of gene 313 
therapy. Many studies on cartilage gene therapy have focused on extending the time of 314 
production and availability of IGF-I. Adeno-associated virus (AAV), a non-pathologic human 315 
parvovirus, is capable of transfecting non-dividing cells for extended periods of time and can 316 
transduce normal and osteoarthritic articular cartilage in vitro[44]. Adenoviral vectors (Ade.IGF-317 
I) have been used to transduce cells where production of IGF-I ranges from 21 days up to 150318 
days[45,46]. Also, chondrocytes transduced with recombinant adeno-associated virus 319 
(rAAV)[47] have produced IGF-I for over 20 days. While our approach described here focused 320 
on plasmid transfection, such an approach can also be used with any of the above vectors. 321 
Tuning both IGF-I production and binding could enable even more extended availability of the 322 
growth factor. 323 
Both IGF-I as a target growth factor[48,49] and alginate as a delivery vehicle[50,51] have 324 
been used in vivo to enhance the repair of cartilage. The modified alginate presented here shows 325 
great promise to further improve chondrocyte matrix production and cartilage repair in vivo[50]. 326 
We noted a robust staining for type II collagen, particularly at higher concentrations of 327 
KPLHALL constructs (See supplementary figure S3). Furthermore, the DNA analysis showed 328 
similar amounts of DNA throughout all the groups throughout the duration of the experiments. 329 
This data, in combination with the matrix synthesis data suggests that a relatively uniform 330 
number of cells was maintained during culture (See supplementary figure S4). This new 331 
biomaterial can be incorporated into other studies that have used alginate as a scaffold or have 332 
used other vectors[48,52]. Overall, these data suggest that combining gene therapy with targeted 333 
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modification of scaffold material provides a platform where cellular production and extracellular 334 
binding of IGF-I act synergistically to enhance cellular biosynthesis. IGF-I regulates many other 335 
tissues including spinal cord[53], heart[54] and brain[55,56]. As such, these studies suggest the 336 
possibility of using such modified biomaterial not only with chondrocytes, but with other cell 337 
types. Furthermore, this approach can be extracted for use with other growth factors, such as 338 
TGF-β and BMP-2, that also have known protein binding sites in extracellular matrix[57,58]. 339 
5. CONCLUSION340 
Modifying alginate with the peptide KPLHALL from the binding pocket of IGFBP-5 341 
enhanced binding affinity more than 10-fold, extended IGF-I availability over 30 days and 342 
increased GAG and HYPRO synthesis 7 and 20 fold respectively. The approach of controlling 343 
growth factor binding, by the grafting of small peptides for biomaterials represents an important 344 
new approach to drug delivery and tissue engineering. 345 
346 
Figure Captions 347 
Figure 1 348 
1A Reaction Scheme: EDC and Sulfo-NHS activate the alginate forming a carboxylate carbon 349 
intermediate. The carboxylate carbon intermediate is attacked by the primary amine nitrogen 350 
forming the amide bond to the alginate backbone. 351 
1B NMR Spectra: First spectra shows the alginate sample with broad peaks for a 352 
polysaccharide, from 4.8 to 3.2, and distinct peak for the anomeric proton[59]. Second spectrum, 353 
mixture of the alginate and peptide, shows both different peaks for alginate and high leucine 354 
amino acids peaks. The third spectrum shows the modified alginate with KPLHALL where the 355 
chemical shift in the leucine peaks and the height of the peaks differs from the mixture. 356 
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1C SPR Spectra and Langmuir’s Affinity Kinetics Model: Representative examples of curve 357 
fits for the affinity kinetic analysis of control (alginate) and modified alginate (KPLHALL 358 
alginate). Concentrations of IGF-I for alginate varied from 3000 nM to 0 nM. Concentrations of 359 
IGF-I for KPLHALL alginate varied from 1000 nM to 0 nM. 360 
 Langmuir’s Affinity Kinetics Model for alginate is the top one (blue) and KPLHALL alginate is 361 
on the bottom (red). KD shifted 10 times, where KD is 50 nM sin KPLHALL alginate (KD of 50 362 
nM) when compared to alginate (KD of 513 nM). KPLHALL alginate had a kon ranging from 1 to 363 
4(10
8/M●sec) and a koff from 5/s to 19/s (R
2
: 0.40 to 0.90).The parameters for alginate kon and364 
koff ranged from 1.6 to 1.8(10
8
/Ms) and koff 10/s to 29/s (R
2
: 0.74 to 0.9).365 
Figure 2 366 
IGF-I Binding 367 
Immunohistochemistry of constructs for IGF-I at Day 30. Scale bar = 100 µm. Alginate does not 368 
show differences in immunolocalization staining at day 30. Immunolocalization staining for IGF-369 
I changes as the concentration of binding sites (KPLHALL) increases in the constructs. The 370 
constructs with 0 µM of binding sites barely show retention of f IGF-I; and constructs with 1 and 371 
3 µM of binding sites show some retention of IGF-I. The highest immunolocalization of IGF-I is 372 
at 100 µM. 373 
Figure 3 374 
3A GAG matrix accumulation kinetic profiles: The production of GAG increases in both 375 
transfected and control groups. Control chondrocytes have smaller changes in kinetic profiles 376 
between the differences in KPLHALL concentrations. pAAV/IGF-I transfected chondrocytes 377 
have a greater effect (*p<0.001 by 2-way ANOVA) between the differences in KPLHALL 378 
concentrations. 379 
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3B HYPRO matrix accumulation kinetic profiles: The production of HYPRO increases in 380 
both pAAV/IGF-I transfected chondrocytes and control chondrocytes. The effect in 381 
chondrocytes that are transfected with pAAV/IGF-I is greater than the effect on those transfected 382 
with pAAV/ MCS (Empty) (p<0.001 by 2-way ANOVA). This effect is greater in concentrations 383 
of 10, 33 and 100 µM binding sites (p<0.001 by 2-way ANOVA). When alginate is compared 384 
with the highest concentration of binding sites (100 µM) there is an increase from 0.08 µg/mg at 385 
0 uM to 1.4 µg/mg at 100 µM (p<0.001 by 2-way ANOVA)in pAAV/IGF-I transfected 386 
chondrocytes. 387 
Figure 4 388 
4A GAG and HYPRO Dose Response: GAG at the steady state concentration of each 389 
concentration is plotted against the different concentrations of binding sites of KPLHALL 390 
covalently attached to alginate. Transfected chondrocytes with pAAV/IGF-I produce 600% 391 
GAG, than the control chondrocytes transfected with pAAV/ MCS (Empty) (*p<0.0001 by 392 
unpaired t test). pAAV/IGF-I transfected chondrocytes required 16.9 µM of binding sites in the 393 
alginate to produce an increase in GAG of 6.9 (Table 2). Control chondrocytes required almost 394 
twice the amount of KPLHALL modified alginate only to produce 60% (Table 2). *p<0.001 395 
when compared to min. +p<0.001 when compared to max empty. 396 
4B Dose Response: The production of HYPRO increases both in pAAV/IGF-I transfected 397 
chondrocytes and control chondrocytes. The effect in chondrocytes that are transfected with 398 
pAAV/IGF-I is greater than the effect in cells transfected with pAAV/ MCS (Empty). 399 
pAAV/IGF-I increased HYPRO accumulation by 20 fold at the maximum effective 400 
concentration of IGF-I binding sites(p<0.02 by  unpaired t test). The parameters are summarized 401 
19 
on table 2 where all R
2 
are higher than 0.93 (Table 2).  %p<0.02 when compared to min. ^p<0.02 402 
when compared to max empty. 403 
 Supplemental 1 404 
Negative Control for IGF-I IHC in 100μM KPLHALL Alginate with pAAV/IGF-I transfected 405 
chondrocytes. Scale bar = 100 µm 406 
 Supplemental 2 407 
Diffusion NMR was performed to see the stability of conjugation in the alginate; the NMR signal 408 
of the leucines is present even as the gradient increases. In contrast to the mixture sample, the 409 
leucine signals disappear as the gradient increases. 410 
Supplemental 3 411 
Immunohistochemistry of constructs for type II collagen at Day 30. Scale bar = 100 µm 412 
Robust staining for type II collagen, particularly at higher concentrations of KPLHALL 413 
constructs.  414 
Supplemental 4 415 
Amount of DNA via Hoechst DNA assay throughout the duration of the experiment. 416 
417 
418 
419 
420 
421 
422 
423 
424 
20 
ACKNOWLEDGMENTS 425 
This research is supported by Alfred P. Sloan Foundation, Coleman Foundation, Award 426 
NIH/NIAMS F31AR061982, NIH Grant R01 AR047702, and the Department of Veterans 427 
Affairs. We would like to thank Dr. Keresztes for his help with the NMR, Dr. Parker for all her 428 
help with the SPR and Ms. Michele Karr for all her help. 429 
430 
REFERENCES 431 
[1] N. Weisleder, N. Takizawa, P. Lin, X. Wang, C. Cao, Y. Zhang, T. Tan, C. Ferrante, H. Zhu, P.-J. 432 
Chen, R. Yan, M. Sterling, X. Zhao, M. Hwang, M. Takeshima, C. Cai, H. Cheng, H. Takeshima, 433 
R.-P. Xiao, J. Ma, Recombinant MG53 Protein Modulates Therapeutic Cell Membrane Repair in 434 
Treatment of Muscular Dystrophy, Sci. Transl. Med. 4 (2012) 139ra85–139. 435 
doi:10.1126/scitranslmed.3003921. 436 
[2] A.H. Nagahara, D. a Merrill, G. Coppola, S. Tsukada, B.E. Schroeder, G.M. Shaked, L. Wang, A. 437 
Blesch, A. Kim, J.M. Conner, E. Rockenstein, M. V Chao, E.H. Koo, D. Geschwind, E. Masliah, 438 
A. a Chiba, M.H. Tuszynski, Neuroprotective effects of brain-derived neurotrophic factor in 439 
rodent and primate models of Alzheimer’s disease., Nat. Med. 15 (2009) 331–337. 440 
doi:10.1038/nm.1912. 441 
[3] K. Bartus, N.D. James, A. Didangelos, K.D. Bosch, J. Verhaagen, R.J. Yáñez-Muñoz, J.H. Rogers, 442 
B.L. Schneider, E.M. Muir, E.J. Bradbury, Large-Scale Chondroitin Sulfate Proteoglycan 443 
Digestion with Chondroitinase Gene Therapy Leads to Reduced Pathology and Modulates 444 
Macrophage Phenotype following Spinal Cord Contusion Injury., J. Neurosci. 34 (2014) 4822–36. 445 
doi:10.1523/JNEUROSCI.4369-13.2014. 446 
[4] 447 
448 
W. Kafienah, F. Al-Fayez, A.P. Hollander, M.D. Barker, Inhibition of cartilage degradation: A 
combined tissue engineering and gene therapy approach, Arthritis Rheum. 48 (2003) 709–718. 
doi:10.1002/art.10842. 449 
[5] C.H. Evans, J.N. Gouze, E. Gouze, P.D. Robbins, S.C. Ghivizzani, Osteoarthritis gene therapy., 450 
Gene Ther. 11 (2004) 379–89. doi:10.1038/sj.gt.3302196. 451 
[6] 452 a J. Nixon, R. a Saxer, B.D. Brower-Toland, Exogenous insulin-like growth factor-I stimulates an 
autoinductive IGF-I autocrine/paracrine response in chondrocytes., J. Orthop. Res. 19 (2001) 26–453 
32. doi:10.1016/S0736-0266(00)00013-9.454 
[7] S. Shi, S. Mercer, S.B. Trippel, Effect of transfection strategy on growth factor overexpression by 455 
articular chondrocytes., J. Orthop. Res. 28 (2010) 103–9. 456 
[8] P. Yu, X. Wang, Y.X. Fu, Enhanced local delivery with reduced systemic toxicity: delivery, 457 
delivery, and delivery., Gene Ther. 13 (2006) 1131–1132. doi:10.1038/sj.gt.3302760. 458 
21 
[9] H. Madry, D. Zurakowski, S.B. Trippel, Overexpression of human insulin-like growth factor-I 459 
promotes new tissue formation in an ex vivo model of articular chondrocyte transplantation., Gene 460 
Ther. 8 (2001) 1443–9. 461 
[10] H. Madry, G. Kaul, M. Cucchiarini, U. Stein, D. Zurakowski, K. Remberger, M.D. Menger, D. 462 
Kohn, S.B. Trippel, Enhanced repair of articular cartilage defects in vivo by transplanted 463 
chondrocytes overexpressing insulin-like growth factor I (IGF-I)., Gene Ther. 12 (2005) 1171–9. 464 
[11] R.A. Saxer, S.J. Bent, B.D. Brower-Toland, Z. Mi, P.D. Robbins, C.H. Evans, a J. Nixon, Gene 465 
mediated insulin-like growth factor-I delivery to the synovium., J. Orthop. Res. 19 (2001) 759–67. 466 
[12] H. Madry, M. Cucchiarini, Advances and challenges in gene-based approaches for osteoarthritis., 467 
J. Gene Med. 15 (2013) 343–55. doi:10.1002/jgm.2741. 468 
[13] I. Hellgren, V. Drvota, R. Pieper, S. Enoksson, P. Blomberg, K.B. Islam, C. Sylvén, Highly 469 
efficient cell-mediated gene transfer using non-viral vectors and FuGene6: in vitro and in vivo 470 
studies., Cell. Mol. Life Sci. 57 (2000) 1326–33. http://www.ncbi.nlm.nih.gov/pubmed/11028922. 471 
[14] L.R. Goodrich, C. Hidaka, P.D. Robbins, C.H. Evans, A.J. Nixon, Genetic modification of 472 
473 chondrocytes with insulin-like growth factor-1 enhances cartilage healing in an equine model., J. 
Bone Joint Surg. Br. 89 (2007) 672–685. doi:10.1302/0301-620X.89B5.18343. 474 
[15] B.D. Brower-Toland, R. a Saxer, L.R. Goodrich, Z. Mi, P.D. Robbins, C.H. Evans, a J. Nixon, 475 
Direct adenovirus-mediated insulin-like growth factor I gene transfer enhances transplant 476 
chondrocyte function., Hum. Gene Ther. 12 (2001) 117–29. 477 
[16] Brigham, Standard of Care : Autologous Chondrocyte Implantation ( ACI ), 34 (2007) 1–8. 478 
[17] W. Kalus, M. Zweckstetter, C. Renner, Y. Sanchez, J. Georgescu, M. Grol, D. Demuth, R. 479 
Schumacher, C. Dony, K. Lang, T. a Holak, Structure of the IGF-binding domain of the insulin-480 
like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor 481 
interactions., EMBO J. 17 (1998) 6558–72. doi:10.1093/emboj/17.22.6558. 482 
[18] J.I. Jones, A. Gockerman, W.H. Busby, C. Camacho-Hubner, D.R. Clemmons, Extracellular 483 
matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I., 484 
J. Cell Biol. 121 (1993) 679–87. 485 
[19] P. Ducheyne, R.L. Mauck, D.H. Smith, Biomaterials in the repair of sports injuries., Nat. Mater. 486 
11 (2012) 652–4. doi:10.1038/nmat3392. 487 
[20] T. Guo, J. Zhao, J. Chang, Z. Ding, H. Hong, J. Chen, J. Zhang, Porous chitosan-gelatin scaffold 488 
containing plasmid DNA encoding transforming growth factor-??1 for chondrocytes proliferation, 489 
Biomaterials. 27 (2006) 1095–1103. doi:10.1016/j.biomaterials.2005.08.015. 490 
[21] X. Zhao, S.B. Yu, F.L. Wu, Z. Bin Mao, C.L. Yu, Transfection of primary chondrocytes using 491 
492 chitosan-pEGFP nanoparticles, J. Control. Release. 112 (2006) 223–228. 
doi:10.1016/j.jconrel.2006.01.016. 493 
22 
[22] M. Thanou, B.I. Florea, M. Geldof, H.E. Junginger, G. Borchard, Q uaternized chitosan oligomers 494 
as novel gene delivery vectors in epithelial cell lines, Biomaterials. 23 (2002) 153–159. 
495 
[23] S.M. Richardson, J.M. Curran, R. Chen, A. Vaughan-Thomas, J. a. Hunt, A.J. Freemont, J.A. 496 
Hoyland, The differentiation of bone marrow mesenchymal stem cells into chondrocyte-like cells 497 
on poly-l-lactic acid (PLLA) scaffolds, Biomaterials. 27 (2006) 4069–4078. 498 
doi:10.1016/j.biomaterials.2006.03.017. 499 
[24] Y. Yao, Y. He, Q. Guan, Q. Wu, Biomaterials A tetracycline expression system in combination 500 
with Sox9 for cartilage tissue engineering, Biomaterials. 35 (2014) 1898–1906. 501 
doi:10.1016/j.biomaterials.2013.11.043. 502 
[25] C. Liu, P. Zhang, X. Zhai, F. Tian, W. Li, J. Yang, Y. Liu, H. Wang, W. Wang, W. Liu, 503 
Biomaterials Nano-carrier for gene delivery and bioimaging based on carbon dots with PEI-504 
passivation enhanced fl uorescence, Biomaterials. 33 (2012) 3604–3613. 505 
doi:10.1016/j.biomaterials.2012.01.052. 506 
[26] X.A. Chen, L.J. Zhang, Z.J. He, W.W. Wang, B. Xu, Q. Zhong, X.T. Shuai, L.Q. Yang, Y. Bin 507 
Deng, Plasmid-encapsulated polyethylene glycol-grafted polyethylenimine nanoparticles for gene 508 
delivery into rat mesenchymal stem cells., Int. J. Nanomedicine. 6 (2011) 843–853. 509 
doi:10.2147/IJN.S17155. 510 
[27] H. Madry, M. Cucchiarini, U. Stein, K. Remberger, M.D. Menger, D. Kohn, S.B. Trippel, 511 
Sustained transgene expression in cartilage defects in vivo after transplantation of articular 512 
chondrocytes modified by lipid-mediated gene transfer in a gel suspension delivery system., J. 513 
Gene Med. 5 (2003) 502–9. 514 
[28] J. a Rowley, G. Madlambayan, D.J. Mooney, Alginate hydrogels as synthetic extracellular matrix 515 
materials., Biomaterials. 20 (1999) 45–53. 516 
[29] D.L. Hern, J. a. Hubbell, Incorporation of adhesion peptides into nonadhesive hydrogels useful for 517 
tissue resurfacing, J. Biomed. Mater. Res. 39 (1998) 266–276. doi:10.1002/(SICI)1097-518 
4636(199802)39:2<266::AID-JBM14>3.0.CO;2-B. 519 
[30] J. a Marcum, R.D. Rosenberg, Anticoagulantly active heparin-like molecules from vascular 520 
tissue., Biochemistry. 23 (1984) 1730–1737. doi:10.1016/0014-4827(86)90525-2. 521 
[31] N.; Packer, N.; Karlsson, Surface Plasmon Resonance Methods and Protocols, Methods in 522 
Molecular Biology, 2010. doi:10.1007/978-1-60761-670-2. 523 
[32] J.J. Ballyns, T.M. Wright, L.J. Bonassar, Effect of media mixing on ECM assembly and 524 
mechanical properties of anatomically-shaped tissue engineered meniscus., Biomaterials. 31 525 
(2010) 6756–63. doi:10.1016/j.biomaterials.2010.05.039. 526 
[33] I.N. Aguilar, S. Trippel, L.J. Bonassar, Comparison of Efficacy of Endogenous and Exogenous 527 
IGF-I in Stimulating Matrix Production in Neonatal and Mature Chondrocytes, 14853 (2015) 1–528 
22. doi:10.1177/1947603515578691.529 
23 
[34] G.A. Kim YJ, Sah R, Doongoe-Yuan H, Fluorometric Assay  of DNA in Cartilage Explants Using 530 
Hoechst 33258 Cartilage Explant Sample Preparation, Anal. Bochemistry. 174 (1988) 168–176. 531 
[35] B.O. Enobakhare, D.L. Bader, D.A. Lee, Quantification of Sulfated Glycosaminoglycans in 532 
Chondrocyte / Alginate Cultures , by Use of 1,9 Dimethylmethylene Blue, Anal. Bochemistry. 243 533 
(1996) 191–194. 534 
[36] R.E. Neuman, M.A. Logan, The determination of hydroxyproline, J. Biol. Chem. (1949) 229–306. 535 
doi:10.1016/0009-8981(65)90038-0. 536 
[37] W. Sauermann, T.J. Feuerstein, Some Mathematical Models for Concentration-Response 537 
Relationships, Biometrical J. 40 (1998) 865–881. 538 
[38] W. Zesławski, H.G. Beisel, M. Kamionka, W. Kalus, R. a Engh, R. Huber, K. Lang, T. a Holak, 539 
The interaction of insulin-like growth factor-I with the N-terminal domain of IGFBP-5., EMBO J. 540 
20 (2001) 3638–44. doi:10.1093/emboj/20.14.3638. 541 
[39] N.G. Genes, J. a Rowley, D.J. Mooney, L.J. Bonassar, Effect of substrate mechanics on 542 
chondrocyte adhesion to modified alginate surfaces., Arch. Biochem. Biophys. 422 (2004) 161–7. 543 
doi:10.1016/j.abb.2003.11.023. 544 
[40] L.M. Mullen, S.M. Best, R. a Brooks, S. Ghose, J.H. Gwynne, J. Wardale, N. Rushton, R.E. 545 
Cameron, Binding and release characteristics of insulin-like growth factor-1 from a collagen-546 
glycosaminoglycan scaffold., Tissue Eng. Part C. Methods. 16 (2010) 1439–48. 547 
doi:10.1089/ten.TEC.2009.0806. 548 
[41] R. Miller, A.J. Grodzinsky, K. Cummings, A. Plaas, A. Cole, R.T. Lee, P. Patwari, M.D.D. Sc, 549 
Intra-articular Injection of HB-IGF-1 Sustains Delivery of IGF-1 to Cartilage through Binding to 550 
Chondroitin Sulfate, 62 (2011) 3686–3694. doi:10.1002/art.27709.Intra-articular. 551 
[42] J. Bonadio, Tissue engineering via local gene delivery, J. Mol. Med. 78 (2000) 303–311. 552 
doi:10.1007/s001090000118. 553 
[43] J. Elisseeff, W. McIntosh, K. Fu, B.T. Blunk, R. Langer, Controlled-release of IGF-I and TGF-554 
beta1 in a photopolymerizing hydrogel for cartilage tissue engineering., J. Orthop. Res. 19 (2001) 555 
1098–1104. doi:10.1016/S0736-0266(01)00054-7. 556 
[44] H. Madry, M. Cucchiarini, E.F. Terwilliger, S.B. Trippel, Recombinant adeno-associated virus 557 
558 vectors efficiently and persistently transduce chondrocytes in normal and osteoarthritic human 
articular cartilage., Hum. Gene Ther. 14 (2003) 393–402. doi:10.1089/104303403321208998. 559 
[45] A.F. Steinert, G.D. Palmer, C. Pilapil, U. Nöth, C.H. Evans, S.C. Ghivizzani, Enhanced in vitro 560 
chondrogenesis of primary mesenchymal stem cells by combined gene transfer., Tissue Eng. Part 561 
A. 15 (2009) 1127–1139. doi:10.1089/ten.tea.2007.0252. 562 
[46] H. Madry, M. Cucchiarini, E.F. Terwilliger, S.B. Trippel, Recombinant adeno-associated virus 563 
564 vectors efficiently and persistently transduce chondrocytes in normal and osteoarthritic human 
articular cartilage., Hum. Gene Ther. 14 (2003) 393–402. doi:10.1089/104303403321208998. 565 
24 
[47] A. Weimer, H. Madry, J.K. Venkatesan, G. Schmitt, J. Frisch, A. Wezel, J. Jung, D. Kohn, E.F. 566 
Terwilliger, S.B. Trippel, M. Cucchiarini, Benefits of recombinant adeno-associated virus 
567 
(rAAV)-mediated insulinlike growth factor I (IGF-I) overexpression for the long-term 
568 
reconstruction of human osteoarthritic cartilage by modulation of the IGF-I axis., Mol. Med. 18 
569 
(2012) 346–58. doi:10.2119/molmed.2011.00371. 570 
[48] A.J. Nixon, L.A. Fortier, J. Williams, H. Mohammed, Enhanced Repair of Extensive Articular 
571 
Defects by Insulin-like Growth Factor-I-laden Fibrin Composites, (1999). 572 
[49] L.J. Bonassar, a J. Grodzinsky, E.H. Frank, S.G. Davila, N.R. Bhaktav, S.B. Trippel, The effect of 573 
dynamic compression on the response of articular cartilage to insulin-like growth factor-I., J. 574 
Orthop. Res. 19 (2001) 11–7. doi:10.1016/S0736-0266(00)00004-8. 575 
[50] G. Kaul, M. Cucchiarini, D. Arntzen, D. Zurakowski, M.D. Menger, D. Kohn, S.B. Trippel, H. 576 
Madry, Local stimulation of articular cartilage repair by transplantation of encapsulated 577 
chondrocytes overexpressing human fibroblast growth factor 2 (FGF-2) in vivo., J. Gene Med. 8 578 
(2006) 100–11. doi:10.1002/jgm.819. 579 
[51] K.Y. Lee, M.C. Peters, K.W. Anderson, D.J. Mooney, Controlled growth factor release from 580 
synthetic extracellular matrices., Nature. 408 (2000) 998–1000. doi:10.1038/35050141. 581 
[52] H. Madry, M. Cucchiarini, G. Kaul, D. Kohn, E.F. Terwilliger, S.B. Trippel, T. SB, Menisci Are 582 
583 Efficiently Transduced by Recombinant Adeno-Associated Virus Vectors In Vitro and In Vivo, 
Am. J. Sports Med. 32 (2004) 1860–1865. 584 
[53] G.L. Hinks, R.J. Franklin, Distinctive patterns of PDGF-A, FGF-2, IGF-I, and TGF-beta1 gene 585 
expression during remyelination of experimentally-induced spinal cord demyelination., Mol. Cell. 586 
Neurosci. 14 (1999) 153–168. doi:10.1006/mcne.1999.0771. 587 
[54] O.S. Opgaard, P.H. Wang, IGF-I is a matter of heart, Growth Horm. IGF Res. 15 (2005) 89–94. 588 
doi:10.1016/j.ghir.2005.02.002. 589 
[55] E. Carro, J.L. Trejo, T. Gomez-Isla, D. LeRoith, I. Torres-Aleman, Serum insulin-like growth 590 
factor I regulates brain amyloid-beta levels., Nat. Med. 8 (2002) 1390–1397. doi:10.1038/nm793. 591 
[56] S. Doré, S. Kar, R. Quirion, Rediscovering an old friend, IGF-I: potential use in the treatment of 592 
neurodegenerative diseases., Trends Neurosci. 20 (1997) 326–331. doi:S0166223696010363 [pii]. 593 
[57] S. Schultz-Cherry, S. Ribeiro, L. Gentry, J.E. Murphy-ullrich, Thrombospondin Binds and 594 
Activates the Small and Large Forms of Latent Transforming Growth Factor-b in a Chemically 595 
Defined System, J. Biol. Chem. 269 (1994) 26775–26782. 596 
[58] a. Sweatt, D.C. Sane, S.M. Hutson, R. Wallin, Matrix Gla protein (MGP) and bone morphogenetic 597 
protein-2 in aortic calcified lesions of aging rats, J. Thromb. Haemost. 1 (2003) 178–185. 598 
doi:10.1046/j.1538-7836.2003.00023.x. 599 
[59] D.J. Mooney, Presentation of BMP - 2 Mimicking Peptides in 3D Hydrogels Directs Cell Fate 600 
Commitment in Osteoblasts and Mesenchymal Stem Cells, (2013). 601 
Figure 1
Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3
Click here to download high resolution image
Figure 4
Click here to download high resolution image
Supplementary S1
Click here to download high resolution image
Supplementary S2
Click here to download high resolution image
Supplementary S3
Click here to download high resolution image
Supplementary S4
Click here to download high resolution image
